Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment
23
Participants
Timeline
Start Date
September 14, 2020
Primary Completion Date
October 16, 2023
Study Completion Date
October 16, 2023
Conditions
Allergic Contact Dermatitis
Interventions
DRUG
Baricitinib
Baricitinib 2 mg
DRUG
Placebo
Placebo
Trial Locations (1)
45324
Wright State Physicians, Fairborn
All Listed Sponsors
lead
Wright State Physicians
OTHER
NCT03945760 - Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects | Biotech Hunter | Biotech Hunter